The Abridged Evaluation of New Drugs pathway has been developed by the Thailand Food and Drug Administration of Thailand.

When relevant, the agency relies on prior decisions from Australia Canada EU-EMA Japan Singapore Switzerland United Kingdom United States

NCEs and other New Drugs = 200 Working Days; Priority Review NCEs and other New Drugs = 150 Working Days.